Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

NCR graphs - Age specific incidence rates

- All cancer age-specific incidence rates, including non-melanoma skin cancer, males, Lebanon, 2005, 2010, 2015
- All cancer age-specific incidence rates, including non-melanoma skin cancer, females, Lebanon, 2005, 2010, 2015

- All cancer age-specific incidence rates, excluding non-melanoma skin cancer, males, Lebanon, 2005, 2010, 2015
- All cancer age-specific incidence rates, excluding non-melanoma skin cancer, females, Lebanon, 2005, 2010, 2015

- Oesophagus cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Oesophagus cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Estomac cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Estomac cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Colo-rectal cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Colo-rectal cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Liver cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Liver cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Gallbladder and extrahepatic bilary tract cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Gallbladder and extrahepatic bilary tract cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Pancreas cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Pancreas cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Larynx cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Larynx cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Trachea-bronchus-lung cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Trachea-bronchus-lung cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Bone cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Bone cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Melanoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Melanoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Non-melanoma skin cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Non-melanoma skin cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Breast cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Breast cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Col uteri cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
- Corpus uteri cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
- Ovary cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Prostate cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Testis cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015

- Kidney cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Kidney cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Bladder cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Bladder cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Brain and central nervous system cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Brain and central nervous system cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Thyroid cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Thyroid cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Hodgkin's lymphoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Hodgkin's lymphoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Non-Hodgkin lymphoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Non-Hodgkin lymphoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Multiple Myeloma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Multiple Myeloma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Lymphoid leukemia age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Lymphoid leukemia age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Myeloid leukemia age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Myeloid leukemia age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
 
    2
ATC Name B/G Ingredients Dosage Form Price
N02CC01 IMIGRAN B Sumatriptan (succinate) - 50mg 50mg Tablet, film coated 378,964 L.L
G03AC08 IMPLANON NXT B Etonogestrel - 68mg 68mg Implant 12,299,971 L.L
L04AX06 IMNOVID B Pomalidomide - 2mg 2mg Capsule, hard 407,188,707 L.L
L04AX06 IMNOVID B Pomalidomide - 4mg 4mg Capsule, hard 417,741,356 L.L
M01AB01 INDOCID B Indometacin - 100mg 100mg Suppository 424,910 L.L
N05AX13 INVEGA B Paliperidone - 9mg 9mg Tablet, extended release 5,825,557 L.L
N05AX13 INVEGA B Paliperidone - 3mg 3mg Tablet, extended release 5,386,121 L.L
N05AX13 INVEGA B Paliperidone - 6mg 6mg Tablet, extended release 5,825,557 L.L
C08DA01 ISOPTIN B Verapamil (HCl) - 80mg 80mg Tablet, film coated 382,554 L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 100mg 100mg Injectable suspension, prolonged release 18,342,148 L.L
C08DA01 ISOPTIN SR B Verapamil (HCl) - 240mg 240mg Tablet, film coated, prolonged release 1,085,822 L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 75mg 75mg Injectable suspension, prolonged release 14,659,577 L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 50mg 50mg Injectable suspension, prolonged release 9,661,754 L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 150mg 150mg Injectable suspension, prolonged release 26,434,190 L.L
J01DH03 INVANZ B Ertapenem - 1g 1g Injectable concentrated powder for solution 3,785,604 L.L
A10BD09 INCRESYNC B Pioglitazone - 15mg, Alogliptin - 25mg Tablet, film coated 3,897,143 L.L
A10BD09 INCRESYNC B Pioglitazone - 30mg, Alogliptin - 25mg Tablet, film coated 3,897,143 L.L
D06BA51 IALUGEN PLUS B Silver sulfadiazine - 10mg/g, Sodium hyaluronate - 2mg/g Cream 1,064,323 L.L
D06BA51 IALUGEN PLUS B Silver sulfadiazine - 10mg/g, Sodium hyaluronate - 0.5mg/g Gauze 1,463,444 L.L
J06BA02 IMMUNOREL BioHuman Human normal immunoglobulin - 5g/100ml 5% Injectable solution 29,700,912 L.L
J06BA02 IMMUNOREL BioHuman Human normal immunoglobulin - 2.5g/50ml 5% Injectable solution 14,850,456 L.L
J06BA02 IG VENA BioHuman Human normal immunoglobulin - 10g/200ml 10g/200ml Injectable solution 53,767,929 L.L
J06BA02 IG VENA BioHuman Human normal immunoglobulin - 1g/20ml 1g/20ml Injectable solution 7,474,948 L.L
J06BB01 IMMUNORHO BioHuman Human anti-D (rh) immunoglobulin - 300mcg 300mcg Injectable dry powder+diluent 5,794,649 L.L
J06BB04 IMMUNOGLOBULINE HUMAINE DE L'HEPATITE B LFB BioHuman Hepatitis B immunoglobulin (human) - 100UI/ml 100UI/ml Injectable solution 6,853,730 L.L
J06BB04 IMMUNOGLOBULINE HUMAINE DE L'HEPATITE B LFB BioHuman Hepatitis B immunoglobulin (human) - 500UI/5ml 500UI/5ml Injectable solution 26,599,935 L.L
B02BD04 IMMUNINE BioHuman Plasma coagulation factor IX, human - 600IU 600IU Injectable lyophilised powder for solution+diluent 20,506,214 L.L
J06BA02 IG VENA BioHuman Human normal immunoglobulin - 2.5g/50ml 2.5g/50ml Injectable solution 17,011,323 L.L
J06BA02 IG VENA BioHuman Human normal immunoglobulin - 5g/100ml 5g/100ml Injectable solution 28,622,366 L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution L.L
    2
Sitemap
© Copyrights reserved to Ministry of Public Health 2025